SmartZyme Biopharma
Improving Enzymes for Glucose Monitoring
Company Overview
Snapshot
Founded in November 2013 by David Baram, SmartZyme Biopharma operates with 1–10 employees. The company has raised $10.5 million across 3 funding rounds from 3 investors.
Business overview
SmartZyme Biopharma develops novel enzymes for various medical applications, leveraging its proprietary protein engineering platform, Provolution. This platform combines advanced computational methods with a random mutagenesis approach to design enzymes with improved clinical performance, focusing on efficacy and safety. The company initially targets products for diabetes patients, including glucose monitoring test strips and patches, operating within the Health Tech & Life Sciences sector.
Strategic signal
In December 2018, Carnot BioSciences, a spin-off of SmartZyme BioPharma, partnered with HemoShear Therapeutics to develop protein-based therapeutics for rare metabolic diseases. This collaboration signals SmartZyme's strategic move to leverage its core technology through spin-offs and partnerships, indicating a potential for broader application of its enzyme engineering capabilities beyond its initial focus on diabetes.
Log in to access full profile ›Company Intelligence Q&A
- What is SmartZyme Biopharma's primary focus?
- SmartZyme Biopharma focuses on improving enzymes for glucose monitoring and other medical applications, particularly for diabetes patients.
- When was SmartZyme Biopharma founded?
- SmartZyme Biopharma was founded in November 2013.
- What is the Provolution platform?
- The Provolution platform is SmartZyme Biopharma's proprietary protein engineering system that uses advanced computational methods and random mutagenesis to design enzymes for improved clinical performance.
- Which investors participated in SmartZyme Biopharma's March 2018 funding round?
- In March 2018, SmartZyme Biopharma received funding from Virtus Inspire Ventures and OrbiMed.
- What significant partnership did a SmartZyme Biopharma spin-off announce?
- In December 2018, Carnot BioSciences, a spin-off of SmartZyme BioPharma, partnered with HemoShear Therapeutics to develop protein-based therapeutics for rare metabolic diseases.